David A. Siegel Day One Biopharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 115,100 shares of DAWN stock, worth $1.57 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
115,100
Previous 84,300
36.54%
Holding current value
$1.57 Million
Previous $1.16 Million
38.07%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding DAWN
# of Institutions
178Shares Held
84MCall Options Held
144KPut Options Held
218K-
Ra Capital Management, L.P. Boston, MA7.87MShares$107 Million1.53% of portfolio
-
Atlas Venture Life Science Advisors, LLC6.43MShares$87.6 Million11.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.89MShares$80.2 Million0.0% of portfolio
-
Braidwell LP Stamford, CT4.87MShares$66.4 Million1.92% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$61.7 Million0.0% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $1B
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...